Credit Suisse Group Lowers Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Hold
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was downgraded by research analysts at Credit Suisse Group to a “hold” rating in a research report issued to clients and investors on Friday. They currently have a $485.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s target price points to a potential downside of 3.94% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Leerink Swann set a $448.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 28th. BTIG Research restated a “buy” rating and set a $460.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, March 20th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target on the stock in a report on Thursday, April 27th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target on the stock. in a report on Monday, April 24th. Finally, Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $375.00 to $484.00 in a report on Friday, May 5th. One research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $456.54.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down 0.03% during mid-day trading on Friday, hitting $504.90. The stock had a trading volume of 608,260 shares. The firm’s 50-day moving average is $474.83 and its 200 day moving average is $400.97. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The stock has a market cap of $53.30 billion, a PE ratio of 61.12 and a beta of 1.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.57 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post $12.73 EPS for the current year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now directly owns 14,000 shares in the company, valued at $6,755,700. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 3,000 shares of the business’s stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $1,350,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in REGN. IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the period. Korea Investment CORP raised its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the period. Advisory Services Network LLC raised its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. WFG Advisors LP raised its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares during the period. Finally, Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 34 shares during the period. Hedge funds and other institutional investors own 66.90% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.